Nutrition - Pharma Stocks in the News: Embark Holdings, GNC, Vitamin Shoppe, Gilead Sciences, Pfizer

 Nutrition - Pharma Stocks in the News: Embark Holdings, GNC, Vitamin Shoppe,
                           Gilead Sciences, Pfizer

PR Newswire

CORAL SPRINGS, Florida, June 26, 2013

CORAL SPRINGS, Florida, June 26, 2013 /PRNewswire/ --

FinancialNewsMedia.com issues market news updates for today's active sports
nutrition & pharmaceutical companies: Embark Holdings, Inc. (OTC: EMBK), GNC
Holdings, Inc. (NYSE: GNC), Vitamin Shoppe, Inc. (NYSE:VSI), Gilead Sciences,
Inc. (NASDAQ: GILD) and Pfizer Inc. (NYSE: PFE)

Headline News Alert:Embark Holdings, Inc. (OTC: EMBK) subsidiary Muscle
Warfare Announces International Distribution Deal out of theUnited Kingdom.
EMBK announced Tuesday that its wholly owned subsidiary Muscle Warfare, Inc.
has increased the size of its current distribution deal with its strong and
fast growing partner in the United Kingdom.The distribution rights for Muscle
Warfare's complete line of elite products granted to UK partner Power Body
Nutrition Ltd. has been increased to hit a minimum of 200k in sales for
2013.Muscle Warfare receives very strong support from our UK partner and
clear proof of this support was Muscle Warfare being the premier United States
based Sports Nutrition Brand, highlighted at their very own and highly popular
Power Body Expo. Located in Birmingham, England, the Power Body Expo put the
Muscle Warfare brand on strong display from May 17-19th with an incredible
looking and centrally located 17 x 33 foot custom made and fully staffed booth
to headline their U.S. based distribution partner.Read the full release at
http://www.financialnewsmedia.com/stock-investing-business-investing-news/featured-news.php?id=283.

GNC Holdings, Inc. (NYSE: GNC), headquartered in Pittsburgh, PA, is a leading
global specialty retailer of health and wellness products, including vitamins,
minerals, and herbal supplement products, sports nutrition products and diet
products.GNC's sales growth this last quarter was up approximately 6%, with
net income per share up an estimated 21%. GNC's cash flow yield is
approximately 4.6% with an estimated $1.1 billion in debt. Muscle Warfare,
Inc., subsidiary of EMBK, announced recently the launch of its elite sports
nutrition brands at select GNC (NYSE: GNC) stores throughout the nation.

Vitamin Shoppe, Inc. (NYSE:VSI) is a leading specialty retailer and direct
marketer of nutritional products based in North Bergen, New Jersey. The
company sells vitamins, minerals, nutritional supplements, herbs, sports
nutrition formulas, homeopathic remedies, green living products, and health
and beauty aids to customers located primarily in the United States. VSI
carries national brand products as well as exclusive products under the
Vitamin Shoppe, BodyTech and True Athlete proprietary brands. Muscle Warfare,
Inc products are also distributing product in all 550+ Vitamin Shoppe (NYSE:
VSI) stores Nationwide.

Gilead Sciences, Inc. (NASDAQ: GILD) recently announced interim results from a
single-arm, open-label Phase 2 study (Study 101-09) evaluating idelalisib
(formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K
delta, for the treatment of patients with indolent non-Hodgkin's lymphoma
(iNHL) that is refractory (non-responsive) to rituximab and to
alkylating-agent-containing chemotherapy. Previously, this has been a largely
unstudied population for which there is significant unmet medical need for
effective therapy. In the study, single-agent treatment with idelalisib
achieved an overall response rate of 53.6 percent, with a median duration of
response at this interim analysis of 11.9 months.

Pfizer Inc. (NYSE: PFE) this week announced that, based on preliminary
results, its previously announced offer to its shareholders to exchange all,
some or none of their shares of Pfizer common stock for shares of Zoetis Inc.
(NYSE: ZTS) common stock owned by Pfizer was oversubscribed. The exchange
offer expired at 12:00 midnight, New York City time, on June 21, 2013. Under
the terms of the exchange offer, 0.9898 shares of Zoetis common stock will be
exchanged for each share of Pfizer common stock accepted in the exchange
offer.

FinancialNewsMedia.comisaleading provider of third party publishing &news
dissemination services. If you would like more information regarding our news
coverage solutions, please visithttp://www.financialnewsmedia.comfor more
details. Get an edge on the market with ourPremium News Alertsthat are FREE
for a limited time athttp://www.financialnewsmedia.com/.Follow us on
Facebook:http://www.facebook.com/financialnewsmediaand
Twitter:http://twitter.com/FNMgroup

DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels.FNMG is NOT affiliated in any manner
with any company mentioned herein.FNMG and its affiliated companies are a
news dissemination and financial marketing solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. FNMG's market updates,
news alerts and corporate profiles are NOT a solicitation or recommendation to
buy, sell or hold securities.The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted as research
material.All readers are strongly urged to perform research and due diligence
on their own and consult a licensed financial professional before considering
any level of investing in stocks. The companies that are discussed in this
release may or may not have approved the statements made in this release. FNMG
is not liable for any investment decisions by its readers or subscribers.
Investors are cautioned that they may lose all or a portion of their
investment when investing in stocks.

FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. FOR FULL
DISCLOSURES, PLEASE VISIT http://www.financialnewsmedia.com/disclaimer.php

This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. "Forward-looking statements"
describe future expectations, plans, results, or strategies and are generally
preceded by words such as "may", "future", "plan" or "planned", "will" or
"should", "expected," "anticipates", "draft", "eventually" or "projected". You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors,
and other risks identified in a company's annual report on Form 10-K or 10-KSB
and other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance on
such statements. The forward-looking statements in this release are made as of
the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company: FN Media Group, LLC
Contact email:editor@financialnewsmedia.com
U.S. Phone: +1(954)345-0611
URL: http://www.financialnewsmedia.com

SOURCE FN Media Group LLC
 
Press spacebar to pause and continue. Press esc to stop.